-The Hindu Instead of surveillance technologies, help TB patients by providing rights-based interventions Decades of global neglect have resulted in tuberculosis (TB) becoming the leading cause of adult deaths in most of the global south — it kills nearly two million people a year. This is shocking given that TB is curable and preventable. But there are signs of change as the spotlight shines on TB; including the United Nations Declaration of...

-The Times of India GURUGRAM: Many years back, Sujata Sahu was hiking the heights of Ladakh when she came upon local teachers heading back to Leh to get midday-meal supplies and uniforms for their students, a journey that usually takes a minimum of four days. Seeing such commitment inspired this resident of Sohna Road to start an initiative to improve education for kids in the remotest of villages. "Since then, I have...

-Livemint.com Distributing biofortified staple foods via government schemes such as Midday Meal can help in the battle against hidden hunger Iron deficiency and anemia are well-recognized and persistent problems in India, exacting a toll that goes much beyond measurable health problems. Most Indian government initiatives targeting anemia so far have had limited success in achieving large-scale impact. Solving these problems require an innovative approach that can reach the most affected segment of the...

-The Telegraph Daltonganj: If you are a government schoolteacher in a Palamau village and want your biometric attendance recorded, better be nimble at climbing trees. The Raghubar Das government’s digital dream needs a leg up on a palash tree on the campus of an upgraded plus two school in Sohree Khas village in Satbarwa block, 41km from Daltonganj. Since September 25, when Palamau district administration gave the co-educational school with 800 students a...

-The Telegraph New Delhi: Patients' rights advocates in India on Tuesday filed two oppositions in the Indian patent office, challenging patent claims by the US pharmaceutical company Gilead Sciences for its medicines sofosbuvir and velpatasvir, used to treat hepatitis-C infections. The oppositions filed by the Delhi Network of Positive People (DNP+) challenge Gilead's patent applications for the tablet formulations of the fixed dose combination of sofosbuvir and velpatasvir and a new form...